Cancer immunotherapy, particularly the use of immune checkpoint inhibitors (e.g., PD-1/PD-L1 antibodies), has significantly advanced cancer treatment by activating immune cells and enhancing their ability to target and eliminate tumor cells (47). This evidence concerns the gene CD274 and neoplasm.